Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 16/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500594 | 0.91 | SSTR2 (0.44) | SSTR2KCNH2PARP1CKS1BSKP1 | |
| SCHEMBL20500581 | 0.90 | SSTR2 (0.45) | SSTR2KCNH2PARP1CKS1BSKP1 | |
| SCHEMBL20500489 | 0.89 | SSTR2 (0.44) | SSTR2KCNH2PARP1CKS1BSKP1 | |
| SCHEMBL20500538 | 0.87 | SSTR2 (0.42) | SSTR2KCNH2PARP1CKS1BSKP1 | |
| SCHEMBL23658217 | 0.86 | SSTR2 (0.51) | SSTR2KCNH2PARP1CKS1BSKP1 | |
| SCHEMBL30255208 | 0.83 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL20500438 | 0.83 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL31506643 | 0.82 | SSTR2 (0.60) | SSTR2PARP1SSTR5 | |
| SCHEMBL21810266 | 0.82 | SSTR2 (0.60) | SSTR2PARP1SSTR5 | |
| SCHEMBL30897193 | 0.82 | SSTR2 (0.49) | SSTR2KCNH2PARP1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072598-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072598-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SSTR2 2/4885KCNH2 4091/4885PARP1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.